MCID: OVR012
MIFTS: 42

Ovarian Serous Cystadenocarcinoma malady

Aliases & Classifications for Ovarian Serous Cystadenocarcinoma

About this section
Sources:
8Disease Ontology, 10DISEASES, 44Novoseek, 61UMLS, 39NCIt
See all sources

Aliases & Descriptions for Ovarian Serous Cystadenocarcinoma:

Name: Ovarian Serous Cystadenocarcinoma 8 10 44 61
Cystadenoma, Serous 61
 
Cystadenoma Serous 44
Serous Cystadenoma 8


External Ids:

Disease Ontology8 DOID:5746
NCIt39 C7978

Summaries for Ovarian Serous Cystadenocarcinoma

About this section
Disease Ontology:8 An ovary serous adenocarcinoma that has material basis in glandular epithelium, in which cystic accumulations of retained secretions are formed.

MalaCards based summary: Ovarian Serous Cystadenocarcinoma, also known as cystadenoma, serous, is related to cystadenocarcinoma and adenofibroma. An important gene associated with Ovarian Serous Cystadenocarcinoma is BIRC5 (baculoviral IAP repeat containing 5), and among its related pathways are TP53 network and Vinka Alkaloid Pathway, Pharmacokinetics. The compounds idoxifene and estradiol benzoate have been mentioned in the context of this disorder. Affiliated tissues include ovary and breast, and related mouse phenotypes are hearing/vestibular/ear and adipose tissue.

Related Diseases for Ovarian Serous Cystadenocarcinoma

About this section

Diseases related to Ovarian Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 114)
idRelated DiseaseScoreTop Affiliating Genes
1cystadenocarcinoma32.2MUC16
2adenofibroma31.0MUC16
3breast cancer30.4PGR, ESR1
4adenoma30.4BAX, BIRC5, ESR2, BCL2
5infertility30.2CYP19A1, ESR1, ESR2
6endometriosis29.7MUC16, ESR1, CYP19A1, VEGFA, ESR2, PGR
7leukemia29.7BAX, BIRC5, ESR2, FAS, AKT1, BCL2
8adenocarcinoma28.7AKT1, BCL2, BIRC5, BAX, FAS, MUC16
9cystadenoma11.2
10pancreatitis11.0
11pancreatic serous cystadenoma11.0
12serous cystadenocarcinoma10.9
13pericardial effusion10.5MUC16
14cerebral meningioma10.4PGR
15microcystic adenoma10.4
16ovarian disease10.3MUC16, CYP19A1
17sertoli-leydig cell tumor10.3
18portal hypertension10.3
19obstructive jaundice10.3
20endosalpingiosis10.3
21leydig cell tumor10.3
22struma ovarii10.3
23tuberculosis10.3
24plasma cell leukemia10.3
25ovarian cyst10.3ESR2, MUC16, CYP19A1
26estrogen excess10.2CYP19A1, PGR
27malignant pleural mesothelioma10.2MUC16, BIRC5
28sertoli cell tumor10.2CYP19A1, PGR
29endocrine gland cancer10.2CYP19A1, ESR1
30ovarian hyperstimulation syndrome10.2CYP19A1, VEGFA
31benign meningioma10.2BIRC5, PGR
32progesterone resistance10.2PGR, ESR1
33uterine sarcoma10.2CYP19A1, ESR1
34cutaneous t cell lymphoma10.2BAX, FAS, BIRC5
35von hippel-lindau syndrome10.1
36obesity10.1
37lipoma10.1
38hepatitis10.1
39islet cell tumor10.1
40pancreatic ductal adenocarcinoma10.1
41neuroendocrine carcinoma10.1
42fibroma10.1
43mucinous cystadenocarcinoma10.1
44splenic artery aneurysm10.1
45compartment syndrome10.1
46conjunctivitis10.1
47cystadenofibroma10.1
48mediastinitis10.1
49neuroendocrine tumor10.1
50peritonitis10.1

Graphical network of the top 20 diseases related to Ovarian Serous Cystadenocarcinoma:



Diseases related to ovarian serous cystadenocarcinoma

Symptoms for Ovarian Serous Cystadenocarcinoma

About this section

Drugs & Therapeutics for Ovarian Serous Cystadenocarcinoma

About this section

Drug clinical trials:

Search ClinicalTrials for Ovarian Serous Cystadenocarcinoma

Search NIH Clinical Center for Ovarian Serous Cystadenocarcinoma

Genetic Tests for Ovarian Serous Cystadenocarcinoma

About this section

Anatomical Context for Ovarian Serous Cystadenocarcinoma

About this section

MalaCards organs/tissues related to Ovarian Serous Cystadenocarcinoma:

31
Ovary, Breast

Animal Models for Ovarian Serous Cystadenocarcinoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Ovarian Serous Cystadenocarcinoma:

35 (show all 24)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053779.2CYP19A1, BCL2, ESR2, FAS, BAX
2MP:00053759.0CYP19A1, BCL2, AKT1, ESR1, ESR2
3MP:00053718.9ESR2, BAX, FAS, VEGFA, PGR, ESR1
4MP:00053708.9FAS, AKT1, ESR2, VEGFA, CYP19A1, ESR1
5MP:00028738.8BIRC5, AKT1, CYP19A1, VEGFA, PGR, ESR2
6MP:00053888.6BAX, BCL2, AKT1, ESR1, FAS, VEGFA
7MP:00020068.6BCL2, AKT1, FAS, ESR1, ESR2, PGR
8MP:00053678.3BAX, BCL2, VEGFA, FAS, ESR1, ESR2
9MP:00053908.0FAS, ESR1, ESR2, PGR, VEGFA, USP14
10MP:00053697.9ESR2, BCL2, AKT1, ESR1, PGR, VEGFA
11MP:00053977.9BAX, VEGFA, PGR, ESR2, ESR1, FAS
12MP:00053877.9BAX, BIRC5, BCL2, AKT1, FAS, CYP19A1
13MP:00107717.9AKT1, ESR2, BCL2, FAS, ESR1, PGR
14MP:00053807.9BIRC5, VEGFA, PGR, AKT1, ESR1, NANOG
15MP:00036317.8AKT1, CYP19A1, BAX, BCL2, USP14, FAS
16MP:00030127.8VEGFA, ESR1, USP2, PGR, NANOG, ESR2
17MP:00053787.8CYP19A1, VEGFA, BCL2, USP14, FAS, AKT1
18MP:00053857.8CYP19A1, VEGFA, BCL2, AKT1, FAS, ESR1
19MP:00053797.6USP2, ESR2, VEGFA, FAS, AKT1, BCL2
20MP:00053897.1BAX, CYP19A1, USP14, USP2, VEGFA, PGR
21MP:00053867.0CYP19A1, USP14, USP2, PGR, ESR2, ESR1
22MP:00053766.8BCL2, BIRC5, BAX, ESR2, USP14, AKT1
23MP:00107686.8ESR1, BAX, ESR2, FAS, AKT1, USP14
24MP:00053846.6BAX, CYP19A1, VEGFA, BCL2, BIRC5, AKT1

Publications for Ovarian Serous Cystadenocarcinoma

About this section

Articles related to Ovarian Serous Cystadenocarcinoma:

(show all 13)
idTitleAuthorsYear
1
Ovarian serous cystadenocarcinoma metastasising to the breast. (23445161)
2013
2
Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. (21266826)
2010
3
Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. (18574502)
2008
4
Plasma cell leukemia with ovarian serous cystadenocarcinoma. (17883177)
2007
5
Differential expression of USP2, USP14 and UBE4A between ovarian serous cystadenocarcinoma and adjacent normal tissues]. (17553343)
2007
6
Oncogene ZNF217 amplification on chromosome 20 q in ovarian serous cystadenocarcinoma and its clinical implications]. (16793610)
2006
7
Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. (11201519)
2001
8
Immunohistochemical localization of aromatase and apoptosis-associated proteins in ovarian serous cystadenocarcinoma arising from ovarian endometriosis. (11516810)
2001
9
Successful treatment of an advanced ovarian serous cystadenocarcinoma in pregnancy with cisplatin, adriamycin and cyclophosphamide (CAP) regimen. Case report. (10968352)
2000
10
Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. (9506768)
1998
11
Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen. (2314830)
1990
12
Experiments with tissue cultures from a human ovarian serous cystadenocarcinoma producing cancer antigen 125 (CA125), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). (3165255)
1988
13
Characterization of newly established cell line HUOA from a human ovarian serous cystadenocarcinoma. (3598277)
1987

Variations for Ovarian Serous Cystadenocarcinoma

About this section

Expression for genes affiliated with Ovarian Serous Cystadenocarcinoma

About this section
Search GEO for disease gene expression data for Ovarian Serous Cystadenocarcinoma.

Pathways for genes affiliated with Ovarian Serous Cystadenocarcinoma

About this section

Pathways related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 58)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
9.9BAX, BCL2
29.9BAX, BCL2
3
Show member pathways
IL-9 Signaling Pathway36
Development Thrombopoietin regulated cell processes59
IL-7 Signaling Pathway36
Immune response IL 9 signaling pathway59
9.8AKT1, BIRC5, BAX
49.8AKT1, BAX, BIRC5
59.7AKT1, ESR2, ESR1
69.7AKT1, ESR2, ESR1
7
Show member pathways
Development Ligand independent activation of ESR1 and ESR259
9.7ESR1, AKT1, ESR2
89.7PGR, CYP19A1, ESR2
9
Show member pathways
IL23-mediated signaling events36
Immune response IL 10 signaling pathway59
Angiopoietin receptor Tie2-mediated signaling36
Development PDGF signaling via STATs and NF kB59
Development Angiopoietin Tie2 signaling59
9.7BCL2, BIRC5, AKT1
109.7BCL2, AKT1, BIRC5
11
Show member pathways
9.7ESR1, ESR2, CYP19A1
12
Show member pathways
9.6BAX, BCL2, AKT1
139.6BAX, AKT1, BCL2
14
Show member pathways
9.6BCL2, BAX, AKT1
15
Show member pathways
9.6BAX, BCL2, AKT1
16
Show member pathways
Apoptosis and survival BAD phosphorylation59
Development Alpha 2 adrenergic receptor activation of ERK59
Chemotaxis CXCR4 signaling pathway59
9.6BCL2, BAX, AKT1
179.6AKT1, BCL2, BAX
18
Show member pathways
Prostate Cancer36
Integrated Cancer pathway36
Steroid Biosynthesis36
9.6AKT1, BCL2, BAX
199.6AKT1, BCL2, BAX
20
Show member pathways
Nuclear Receptors36
9.6PGR, ESR2, ESR1
21
Show member pathways
Cell cycle ESR1 regulation of G1 S transition59
Immune response MIF JAB1 signaling59
Cell cycle Cell cycle generic schema 59
9.6ESR1, PGR, AKT1
229.6BCL2, FAS, BAX
23
Show member pathways
9.6FAS, BCL2, BAX
249.6BCL2, AKT1, ESR1
25
Show member pathways
Development VEGF signaling via VEGFR2 generic cascades59
9.5AKT1, ESR1, VEGFA
269.5BCL2, AKT1, VEGFA
27
Show member pathways
Signal transduction PTEN pathway59
9.4AKT1, BIRC5, BCL2, BAX
289.4BAX, BIRC5, BCL2, AKT1
299.4BAX, FAS, BCL2, BIRC5
30
Show member pathways
Apoptosis and survival Apoptotic TNF family pathways59
9.4FAS, BAX, BIRC5, BCL2
31
Show member pathways
FAS pathway and Stress induction of HSP regulation36
Apoptosis and survival FAS signaling cascades59
Caspase cascade in apoptosis36
9.4BAX, AKT1, FAS, BCL2
32
Show member pathways
9.4FAS, AKT1, BCL2, BAX
33
Show member pathways
Apoptosis and survival TNFR1 signaling pathway59
TWEAK Signaling Pathway36
Apoptosis Modulation by HSP7036
HIV-1 Nef- Negative effector of Fas and TNF-alpha36
9.4BAX, BCL2, FAS, AKT1
34
Show member pathways
9.4BCL2, BAX, AKT1, FAS
359.3BAX, BCL2, ESR2, ESR1
36
Show member pathways
Cytoskeleton remodeling FAK signaling59
Development Endothelin 1 EDNRA transactivation of EGFR59
9.3AKT1, ESR1, ESR2, VEGFA
37
Show member pathways
Apoptosis Modulation and Signaling36
Apoptosis36
9.1BCL2, FAS, AKT1, BIRC5, BAX
38
Show member pathways
Toll-like receptor signaling pathway36
Regulation of toll-like receptor signaling pathway36
9.1BAX, BIRC5, BCL2, FAS, AKT1
39
Show member pathways
9.1BAX, BCL2, AKT1, BIRC5, FAS
40
Show member pathways
9.1ESR2, BIRC5, AKT1, BCL2, ESR1
41
Show member pathways
Prolactin Signaling Pathway36
Development Prolactin receptor signaling59
Leptin signaling pathway36
9.1ESR1, AKT1, BCL2, BAX, ESR2
429.0VEGFA, NANOG, ESR2
43
Show member pathways
Development EGFR signaling via PIP359
Development PDGF signaling via MAPK cascades59
Apoptosis and survival Anti apoptotic action of membrane bound ESR159
Signaling of Hepatocyte Growth Factor Receptor36
Development EGFR signaling via small GTPases59
Development Neurotrophin family signaling59
Apoptosis and survival NGF signaling pathway59
Apoptosis and survival Role of CDK5 in neuronal death and survival59
9.0ESR1, BAX, FAS, AKT1, BCL2
44
Show member pathways
9.0AKT1, VEGFA, BCL2, BAX, FAS
45
Show member pathways
8.9AKT1, ESR1, ESR2, NANOG
46
Show member pathways
DNA damage response (only ATM dependent)36
Wnt Signaling Pathway and Pluripotency36
8.8BAX, NANOG, BCL2, AKT1
478.8BAX, VEGFA, AKT1, FAS, BCL2, BIRC5
488.7BCL2, ESR1, BAX, AKT1, CYP19A1, VEGFA
498.4VEGFA, NANOG, AKT1, FAS, ESR1
508.4BCL2, ESR2, ESR1, FAS, BAX, VEGFA

Compounds for genes affiliated with Ovarian Serous Cystadenocarcinoma

About this section

Compounds related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 235)
idCompoundScoreTop Affiliating Genes
1idoxifene449.7PGR, ESR1, CYP19A1
2estradiol benzoate449.7ESR1, PGR, CYP19A1, ESR2
3nandrolone44 2410.7CYP19A1, PGR, ESR1, ESR2
4leuprolide acetate449.7ESR1, ESR2, PGR, CYP19A1
5anastrozole44 50 1111.6ESR1, PGR, CYP19A1, ESR2
6exemestane44 50 60 1112.6ESR1, CYP19A1, PGR, ESR2
7bisphenol a449.6PGR, CYP19A1, ESR2, ESR1
8lapatinib44 50 1111.6BIRC5, PGR, CYP19A1, ESR1
9clomiphene citrate449.6ESR2, ESR1, PGR, CYP19A1
103,3-diindolylmethane449.6BAX, BIRC5, ESR1, VEGFA
11hoechst 33342449.6BCL2, BIRC5, FAS, BAX
12toremifene44 1110.5CYP19A1, PGR, ESR1, FAS, ESR2
13fulvestrant44 50 28 1112.5ESR1, CYP19A1, PGR, ESR2
144-hydroxytamoxifen449.4CYP19A1, PGR, ESR2, ESR1, AKT1
15letrozole44 50 60 1112.4ESR1, ESR2, PGR, CYP19A1
16indole-3-carbinol449.3CYP19A1, ESR1, AKT1, BIRC5, BCL2, BAX
17gefitinib44 50 1111.2BIRC5, AKT1, ESR1, ESR2, VEGFA, CYP19A1
18adriamycin449.2PGR, FAS, AKT1, BAX, BCL2, BIRC5
19celecoxib44 60 28 50 24 1114.2BCL2, AKT1, VEGFA, CYP19A1, BIRC5, BAX
20progestin449.2PGR, VEGFA, ESR2, ESR1, CYP19A1
21gemcitabine44 50 1111.2BAX, BCL2, AKT1, VEGFA, CYP19A1, BIRC5
22thymidylate449.1FAS, ESR2, BIRC5, BAX, VEGFA, BCL2
23trastuzumab44 50 1111.1CYP19A1, VEGFA, PGR, ESR1, FAS, BIRC5
24egcg449.1BAX, VEGFA, ESR2, FAS, BCL2, BIRC5
25taxane449.1ESR1, BCL2, PGR, CYP19A1, VEGFA, BIRC5
26levonorgestrel44 60 28 1112.1ESR1, PGR, CYP19A1, ESR2
27etoposide44 50 60 1112.0BAX, BIRC5, BCL2, FAS, ESR2, AKT1
28mifepristone44 28 60 1111.9CYP19A1, VEGFA, PGR, ESR2, ESR1, BAX
29arsenite44 249.9AKT1, VEGFA, FAS, PGR, BAX, BIRC5
30mg 13244 609.9BIRC5, BCL2, BAX, VEGFA, AKT1, FAS
31docetaxel44 50 60 1111.8CYP19A1, BAX, PGR, BIRC5, BCL2, ESR1
32ly294002448.8ESR1, FAS, AKT1, VEGFA, BCL2, BIRC5
33sb 20358044 609.8BAX, BCL2, AKT1, FAS, VEGFA, BIRC5
34cyclophosphamide44 50 1110.7BCL2, MUC16, ESR1, PGR, VEGFA, CYP19A1
35n acetylcysteine448.7FAS, VEGFA, AKT1, BAX, BCL2, BIRC5
36actinomycin d448.6BCL2, BIRC5, BAX, ESR1, VEGFA, ESR2
37resveratrol44 60 24 1111.6VEGFA, PGR, ESR2, ESR1, FAS, BCL2
385fluorouracil448.5BCL2, BAX, BIRC5, CYP19A1, ESR1, FAS
39testosterone44 60 24 1111.5FAS, MUC16, AKT1, BIRC5, ESR1, ESR2
40cisplatin44 50 60 1111.4MUC16, FAS, AKT1, BCL2, ESR1, BIRC5
41retinoic acid44 249.4BIRC5, BAX, BCL2, AKT1, FAS, ESR2
42dexamethasone44 50 28 1111.1ESR2, VEGFA, CYP19A1, PGR, FAS, AKT1
43genistein44 28 60 1 24 1113.1AKT1, FAS, ESR1, ESR2, PGR, VEGFA
44tamoxifen44 50 28 1111.1PGR, VEGFA, CYP19A1, ESR2, ESR1, BAX
45cycloheximide448.1BIRC5, BAX, AKT1, BCL2, PGR, FAS
46paraffin447.9BAX, BIRC5, BCL2, AKT1, FAS, MUC16
47vegf447.9VEGFA, AKT1, PGR, BCL2, MUC16, ESR1
48estrogen447.9VEGFA, CYP19A1, MUC16, ESR2, PGR, ESR1
49paclitaxel44 50 119.9MUC16, BAX, BIRC5, BCL2, AKT1, FAS
50doxorubicin44 50 119.6CYP19A1, BAX, ESR2, BIRC5, BCL2, FAS

GO Terms for genes affiliated with Ovarian Serous Cystadenocarcinoma

About this section

Cellular components related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1pore complexGO:00469309.8BAX, BCL2
2mitochondrial outer membraneGO:00057419.3PGR, BCL2, BAX
3nucleoplasmGO:00056548.2ZNF217, AKT1, ESR1, ESR2, NANOG, PGR
4nucleusGO:00056347.1NANOG, ESR2, ESR1, FAS, AKT1, BCL2

Biological processes related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 43)
idNameGO IDScoreTop Affiliating Genes
1activation-induced cell death of T cellsGO:000692410.4AKT1, FAS
2transformed cell apoptotic processGO:000692710.3BAX, FAS
3regulation of nitrogen utilizationGO:000680810.3BCL2, BAX
4uterus developmentGO:006006510.3ESR1, ESR2
5regulation of protein heterodimerization activityGO:004349710.3BCL2, BAX
6positive regulation of extrinsic apoptotic signaling pathway in absence of ligandGO:0200124110.3BAX, FAS
7regulation of protein homodimerization activityGO:004349610.3BAX, BCL2
8endoplasmic reticulum calcium ion homeostasisGO:003246910.3BCL2, BAX
9positive regulation of nitric-oxide synthase activityGO:005100010.3ESR1, AKT1
10renal system processGO:000301410.2BCL2, FAS
11response to acidGO:000110110.2BCL2, BAX
12negative regulation of autophagyGO:001050710.2AKT1, BCL2
13negative regulation of apoptotic signaling pathwayGO:0200123410.2BCL2, BAX
14androgen metabolic processGO:000820910.2ESR1, CYP19A1
15cellular response to organic substanceGO:007131010.2BCL2, BAX
16apoptotic mitochondrial changesGO:000863710.2AKT1, BAX
17B cell homeostasisGO:000178210.2BCL2, BAX
18intracellular estrogen receptor signaling pathwayGO:003052010.1ESR1, ESR2
19positive regulation of blood vessel endothelial cell migrationGO:004353610.1VEGFA, AKT1
20mammary gland alveolus developmentGO:006074910.1ESR1, VEGFA
21regulation of mitochondrial membrane potentialGO:005188110.1BAX, BCL2
22vagina developmentGO:006006810.1BAX, ESR1, ESR2
23intrinsic apoptotic signaling pathwayGO:009719310.0AKT1, BCL2, BAX
24negative regulation of cysteine-type endopeptidase activity involved in apoptotic processGO:004315410.0AKT1, VEGFA, BIRC5
25positive regulation of sequence-specific DNA binding transcription factor activityGO:005109110.0ESR2, ESR1, AKT1
26homeostasis of number of cells within a tissueGO:004887310.0BAX, BCL2
27extrinsic apoptotic signaling pathway via death domain receptorsGO:000862510.0BAX, FAS, BCL2
28extrinsic apoptotic signaling pathway in absence of ligandGO:009719210.0BAX, BCL2, FAS
29intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressGO:007005910.0BAX, BCL2
30response to toxic substanceGO:000963610.0FAS, BCL2, BAX
31release of cytochrome c from mitochondriaGO:00018369.9BAX, BCL2
32positive regulation of peptidyl-serine phosphorylationGO:00331389.9BCL2, AKT1, VEGFA
33cellular response to hypoxiaGO:00714569.9AKT1, VEGFA, BCL2
34response to gamma radiationGO:00103329.9BCL2, BAX
35ovarian follicle developmentGO:00015419.7ESR2, VEGFA, BCL2, BAX
36transcription initiation from RNA polymerase II promoterGO:00063679.6PGR, ESR1, ESR2
37positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathwayGO:019007409.6AKT1, BCL2
38apoptotic processGO:00069159.5FAS, BIRC5, BCL2, BAX, AKT1
39negative regulation of apoptotic processGO:00430669.4BCL2, VEGFA, FAS, AKT1, BIRC5
40signal transductionGO:00071659.4ESR2, AKT1, FAS, ESR1, PGR
41positive regulation of mitotic cell cycleGO:00459319.2USP2, NANOG, BIRC5
42ubiquitin-dependent protein catabolic processGO:00065119.0UBE4A, USP14, USP2
43negative regulation of transcription from RNA polymerase II promoterGO:00001228.3USP2, VEGFA, ESR2, NANOG

Molecular functions related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 12)
idNameGO IDScoreTop Affiliating Genes
1estrogen response element bindingGO:003405610.1ESR1, ESR2
2estrogen receptor activityGO:003028410.0ESR2, ESR1
3BH3 domain bindingGO:005143410.0BAX, BCL2
4core promoter sequence-specific DNA bindingGO:00010469.9ESR1, ESR2
5nitric-oxide synthase regulator activityGO:00302359.9AKT1, ESR1
6steroid bindingGO:00054969.8ESR1, ESR2, PGR
7steroid hormone receptor activityGO:00037079.8PGR, ESR2, ESR1
8channel activityGO:00152679.8BAX, BCL2
9enzyme bindingGO:00198999.4PGR, ESR2, ESR1, AKT1, BIRC5
10protein heterodimerization activityGO:00469829.0VEGFA, BCL2, BIRC5, BAX
11identical protein bindingGO:00428028.1BAX, USP2, VEGFA, ESR1, FAS, AKT1
12protein bindingGO:00055155.6ESR1, ESR2, PGR, VEGFA, USP2, USP14

Sources for Ovarian Serous Cystadenocarcinoma

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet